Xencor could face second challenge from former partner
J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.
ASH 2024 preview – best of the rest
Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.
Amgen packs up in Claudin6
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
EHA 2024 – J&J bows out as Roche looks to confirm
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
FibroGen throws down the prostate cancer gauntlet
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
Warning signs for Xencor
Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.
TROP2 gets more crowded
The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.
